Stay updated with breaking news from Numeric Rating Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.
Adult patients with moderate to severe atopic dermatitis (AD) had a 1-year and 1.5-year upadacitinib drug survival of 91.5% and 80.2%, respectively.
In endometriosis, pain catastrophizing significantly affects pain disability, and vice versa, according to new research.
These phase 2 data on hidradenitis suppurativa patients highlight new information on the use of lutikizumab as a treatment alternative.
Julia van der Meulen and co-workers compare procedural sedation and analgesia versus general anesthesia in women undergoing hysteroscopic myomectomy for fibroids.